Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0646 in metastatic colorectal cancer
NCT01175291Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2010
- Primary completion
- Jul 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of dalotuzumab in colorectal cancer (metastatic) (mCRC), sponsored by Moffitt Cancer Center. Planned start Sep 2010; status: withdrawn.
02
Drugs
dalotuzumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01175291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175291.